SOURCE: MindBranch, Inc.

March 22, 2005 15:29 ET

Biotech-Enabled Cancer Therapies to Cross $29 Billion in Revenue by 2008

NORTH ADAMS, MA -- (MARKET WIRE) -- March 22, 2005 -- In 1971, the U.S. Congress passed the National Cancer Act, committing the nation to putting an end to this collection of dread diseases. More than 30 years later, the incidence of cancer is about the same as it was in 1950 and chances of survival are not much better.

However, the recent approvals of biopharmaceuticals like Avastin™, Erbitux™ and Herceptin™, all monoclonal antibody drugs, have given hope that the tide finally is turning. The promise of biotechnology finally is being brought to bear on this most problematic of diseases and its many manifestations.

Beyond Chemotherapy: Battling Cancer with Biotechnology

(, a new study from Business Communications Company, now discusses therapies being developed and assesses the likelihood for success of these new therapies. It quantifies historical and projected sales for biopharmaceutical products to treat cancer and suggests that global revenues from biotech-enabled cancer therapies are expected to rise at an AAGR (average annual growth rate) of 14.5% from $15 billion in 2003 to more than $29 billion in 2008.

Investors, suppliers, medical, pharmaceutical or life science companies interested in learning more about this or other life science reports that are available through MindBranch, Inc. should call 1-413-662-3773.

About MindBranch: MindBranch Inc. is a leading market research services company distributing reports, newsletters, directories, databases, subscription services, country and/or company profiles and custom research in over 130 industry segments from over 400 leading firms. Since 1992, they have recommended market research and helped clients centralize and streamline their research procurement. For more information, visit

About BCC: Since 1971, Business Communications Company, Inc. has studied the major market, economic and technological developments that have characterized industry and produced reports, newsletters and conferences for those industries. With the publication of Applied Genetics News in 1979, BCC was among the first to recognize and report on the massive potential of the present "biotechnology revolution." In addition to an annual conference, BCC publishes 8-10 full-scale market analyses each year, dealing with business opportunities in biotechnology.

Contact Information

  • Contact details:
    Sharon Oakes
    Director, Healthcare Markets Development